Topic:

Regulatory

Latest Headlines

Latest Headlines

GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries

GlaxoSmithKline has added two more countries to its bribery-investigation list. The U.K.-based drugmaker now says it faces probes in Jordan and Lebanon, in addition to recently announced investigations in Iraq and Poland.

Endo's AMS hit with an FDA warning letter

As if the more than $500 million fallout from lawsuits regarding its vaginal mesh devices weren't bad enough, American Medical Systems must now deal with an FDA warning letter on its process validation, risk analysis, and corrective and preventative action procedures at its Minnetonka, MN, facility.

EMA warns Herceptin vials stolen in Italy spreading through EU

Vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up in other places in Europe, leading the European Medicines Agency (EMA) to issue an alert and Herceptin maker Roche to recall all of the batches from which the stolen drugs came.

GlaxoSmithKline bribery probe heats up as Polish prosecutors charge 13 people

Polish prosecutors have charged 13 people in connection with the GlaxoSmithKline bribery probe in their country.

Boston Scientific scores FDA approval for a new crop of implantable cardiac devices

Boston Scientific won FDA approval for a new crop of implantable defibrillators and heart failure devices, helping the company move forward with sales and development of its cardiac rhythm management system.

Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market

GlaxoSmithKline's albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's powerhouse Victoza and AstraZeneca's exanatide franchise.

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

UPDATED: FDA puts import alert on Baxter plant that makes saline solution

Baxter International, which has had a series of recalls in the last few months, has had a plant in Canada banned by the FDA from shipping products, including saline solution, which is already in serious short supply in the U.S.

Devices approved for pediatric use weren't tested in children first, new study finds

As the pediatric medical device sector grows, lawmakers are pushing for the development of innovative products that can treat younger patients and address an unmet need. But most devices that were recently approved for pediatric use were not tested on children first,  Reuters  reported.   

UPDATED: Impax believes manufacturing issues are fixed

Impax Laboratories had its future sidelined by manufacturing problems that set off a domino effect. Now, it says it is ready to get back in the game.